{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:50:37Z","timestamp":1792050637712,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10637-021-01100-x","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T07:02:46Z","timestamp":1616742166000},"page":"1405-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-205X","authenticated-orcid":false,"given":"Andrew W.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"1100_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"1100_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"1100_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.urolonc.2004.04.031","volume":"22","author":"RF S\u00e1nchez-Ortiz","year":"2004","unstructured":"S\u00e1nchez-Ortiz RF, Pettaway CA (2004) The role of lymphadenectomy in penile cancer. Urol Oncol 22:236\u2013244 discussion 44-5","journal-title":"Urol Oncol"},{"key":"1100_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.eururo.2008.04.016","volume":"54","author":"JA Leijte","year":"2008","unstructured":"Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S (2008) Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-Centre analysis of 700 patients. Eur Urol 54:161\u2013168","journal-title":"Eur Urol"},{"key":"1100_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.6004\/jnccn.2013.0195","volume":"11","author":"PE Spiess","year":"2013","unstructured":"Spiess PE (2013) New treatment guidelines for penile cancer. J Natl Compr Cancer Netw 11:659\u2013662","journal-title":"J Natl Compr Cancer Netw"},{"key":"1100_CR6","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA (2010) Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 28:3851\u20133857","journal-title":"J Clin Oncol"},{"key":"1100_CR7","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","volume":"85","author":"J Wang","year":"2015","unstructured":"Wang J, Pettaway CA, Pagliaro LC (2015) Treatment for metastatic penile Cancer after first-line chemotherapy failure: analysis of response and survival outcomes. Urology 85:1104\u20131110","journal-title":"Urology"},{"key":"1100_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/JU.0000000000000746","volume":"203","author":"M Azizi","year":"2020","unstructured":"Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE (2020) Systematic review and meta-analysis-is there a benefit in using Neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma? J Urol 203:1147\u20131155","journal-title":"J Urol"},{"key":"1100_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1389200218666170518162500","volume":"18","author":"SA Mann","year":"2017","unstructured":"Mann SA, Lopez-Beltran A, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L (2017) Targeting the programmed cell Death-1 pathway in genitourinary tumors: current Progress and future perspectives. Curr Drug Metab 18:700\u2013711","journal-title":"Curr Drug Metab"},{"key":"1100_CR10","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T (2017) PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in Cancer. Clin Cancer Res 23:3158\u20133167","journal-title":"Clin Cancer Res"},{"key":"1100_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"},{"key":"1100_CR12","doi-asserted-by":"publisher","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.018","volume":"30","author":"A Marabelle","year":"2019","unstructured":"Marabelle A, Fakih MG, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller W, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Aurora-Garg D, Chen M, Jin F, Norwood K, Bang YJ (2019) Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158. Ann Oncol 30:v477\u2013v4v8","journal-title":"Ann Oncol"},{"key":"1100_CR13","unstructured":"National Comprehensive Cancer Network. Penile cancer (Version 2.2019). https:\/\/www2.tri-kobe.org\/nccn\/guideline\/urological\/english\/penile.pdf. Accessed 10 Jan 2021"},{"key":"1100_CR14","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","volume":"27","author":"AM Udager","year":"2016","unstructured":"Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R (2016) Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol 27:1706\u20131712","journal-title":"Ann Oncol"},{"key":"1100_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","volume":"59","author":"M Cocks","year":"2017","unstructured":"Cocks M, Taheri D, Ball MW, Bezerra SM, del Carmen Rodriguez M, Ricardo BFP, Bivalacqua TJ, Sharma RB, Meeker A, Chaux A, Burnett AL, Netto GJ (2017) Immune-checkpoint status in penile squamous cell carcinoma: a north American cohort. Hum Pathol 59:55\u201361","journal-title":"Hum Pathol"},{"key":"1100_CR16","doi-asserted-by":"publisher","first-page":"e1269047","DOI":"10.1080\/2162402X.2016.1269047","volume":"6","author":"C Deng","year":"2017","unstructured":"Deng C, Li Z, Guo S, Chen P, Chen X, Zhou Q, Chen J, Yu X, Wu X, Ma W, Xie Q, Ye Y, Li Y, Qin Z, Liu Z, Liu R, Zhang Z, Yao K, Han H, Zhou F (2017) Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. Oncoimmunology 6:e1269047","journal-title":"Oncoimmunology"},{"key":"1100_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","volume":"197","author":"SR Ottenhof","year":"2017","unstructured":"Ottenhof SR, Djajadiningrat RS, de Jong J, Thygesen HH, Horenblas S, Jordanova ES (2017) Expression of programmed death ligand 1 in penile Cancer is of prognostic value and associated with HPV status. J Urol 197:690\u2013697","journal-title":"J Urol"},{"key":"1100_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.euo.2018.07.010","volume":"2","author":"S Davidsson","year":"2019","unstructured":"Davidsson S, Carlsson J, Giunchi F, Harlow A, Kirrander P, Rider J, Fiorentino M, Andr\u00e9n O (2019) PD-L1 expression in men with penile Cancer and its association with clinical outcomes. Eur Urol Oncol 2:214\u2013221","journal-title":"Eur Urol Oncol"},{"key":"1100_CR19","doi-asserted-by":"publisher","first-page":"e000347","DOI":"10.1136\/jitc-2019-000347","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347","journal-title":"J Immunother Cancer"},{"key":"1100_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.euf.2019.05.010","volume":"5","author":"DJ Canter","year":"2019","unstructured":"Canter DJ, Nicholson S, Watkin N, Hall E, Pettaway C (2019) The international penile advanced Cancer trial (InPACT): rationale and current status. Eur Urol Focus 5:706\u2013709","journal-title":"Eur Urol Focus"},{"key":"1100_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7150\/jca.8167","volume":"5","author":"LB Jilaveanu","year":"2014","unstructured":"Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM (2014) PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer 5:166\u2013172","journal-title":"J Cancer"},{"key":"1100_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56\u201361","journal-title":"Science"},{"key":"1100_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","volume":"201","author":"JM Jacob","year":"2019","unstructured":"Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio JA, Ramkissoon S, Severson E, Necchi A, Killian JK, Ali SM, Schrock AB, Liu NW, Chung J, Miller VA, Stephens PJ, Welsh A, Corona RJ, Ross JS, Bratslavsky G (2019) Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol 201:541\u2013548","journal-title":"J Urol"},{"key":"1100_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JCO.2019.37.7_suppl.505","volume":"37","author":"J Chahoud","year":"2019","unstructured":"Chahoud J, McCormick BZ, Netto F, Rao P, Pickering CR, Pettaway CA (2019) Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors. J Clin Oncol 37:505","journal-title":"J Clin Oncol"},{"key":"1100_CR25","first-page":"8349793","volume":"2019","author":"G Hui","year":"2019","unstructured":"Hui G, Ghafouri SN, Shen J, Liu S, Drakaki A (2019) Treating penile Cancer in the immunotherapy and targeted therapy era. Case Rep Oncol Med 2019:8349793","journal-title":"Case Rep Oncol Med"},{"key":"1100_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","volume":"41","author":"DT Trafalis","year":"2018","unstructured":"Trafalis DT, Alifieris CE, Kalantzis A, Verigos KE, Vergadis C, Sauvage S (2018) Evidence for efficacy of treatment with the anti-PD-1 Mab Nivolumab in radiation and Multichemorefractory advanced penile squamous cell carcinoma. J Immunother 41:300\u2013305","journal-title":"J Immunother"},{"key":"1100_CR27","doi-asserted-by":"crossref","unstructured":"Baweja A, Mar N (2021) Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. J Oncol Pharm Pract 27(1):212\u2013215","DOI":"10.1177\/1078155220922602"},{"key":"1100_CR28","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.2147\/OTT.S231258","volume":"13","author":"X Su","year":"2020","unstructured":"Su X, Zhang J, Fu C, Xiao M, Wang C (2020) Recurrent metastatic penile Cancer patient with positive PD-L1 expression obtained significant benefit from immunotherapy: a case report and literature review. Onco Targets Ther 13:3319\u20133324","journal-title":"Onco Targets Ther"},{"key":"1100_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000495251","volume":"86","author":"R Stoehr","year":"2019","unstructured":"Stoehr R, Wendler O, Giedl J, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Bertz S, Hartmann A (2019) No evidence of microsatellite instability and loss of mismatch-repair-protein expression in squamous cell carcinoma of the penis. Pathobiology 86:145\u2013151","journal-title":"Pathobiology"},{"key":"1100_CR30","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41467-020-15980-9","volume":"11","author":"T Huang","year":"2020","unstructured":"Huang T, Cheng X, Chahoud J, Sarhan A, Tamboli P, Rao P, Guo M, Manyam G, Zhang L, Xiang Y, Han L, Shang X, Deng P, Luo Y, Lu X, Feng S, Ferrer MM, Alan Wang Y, DePinho RA, Pettaway CA, Lu X (2020) Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun 11:2124","journal-title":"Nat Commun"},{"key":"1100_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1200\/JCO.2018.36.6_suppl.515","volume":"36","author":"RM Nadal","year":"2018","unstructured":"Nadal RM, Mortazavi A, Stein M et al (2018) Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J Clin Oncol 36:515","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01100-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01100-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01100-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:08:24Z","timestamp":1678511304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01100-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01100-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients reported here participated in a clinical trial that was registered on  (NCT02721732). The trial protocol was approved by the US Food and Drug Administration and the institutional review board at MDACC. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All study participants provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients reported here participated in a clinical trial that was registered on  (NCT02721732). The trial protocol was approved by the US Food and Drug Administration and the institutional review board at MDACC. All procedures performed in studies of human subjects were in accordance with the ethical standards of the institutional review board and with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"All study participants provided written informed consent before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Individual patient consent for publication is not necessary because this case series does not include identifying data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Andrew W. Hahn, Jad Chahoud, Jennifer Wang, and Bettzy A. Stephen have no conflicts to disclose.Matthew T. Campbell reports consulting\/honorarium: Eisai, Exelixis, EMD Serono, Pfizer, AstraZeneca, Seattle Genetics, research grant funding: Exelixis, Pfizer, EMD Serono, ApricityHealth, Janssen.Curtis A. Pettaway reports consulting to Wolters Kluwer for \u201cUpToDate series.\u201dAung Naing reports consulting to CytomX Therapeutics, Novartis, Kymab, Genome, OncoSec KEYNOTE-695, and STCube Pharmaceuticals. He reports travel and accommodation expenses from ARMO BioSciences. He reports research funding to his institution from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, and Surface Oncology. Spouse reports research funding to her institution from Immune Deficiency Foundation Jeffery Modell Foundation and chao physician-scientist, and Baxalta; and is on the advisory board of Takeda, CSL, Behring, Horizon, and Pharming.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}